Follow us on Twitter
twitter icon@FreshPatents


Hypertension patents

      

This page is updated frequently with new Hypertension-related patent applications.

SALE: 160+ Hypertension-related patent PDFs



 Methods, systems and devices for treating hypertension patent thumbnailnew patent Methods, systems and devices for treating hypertension
Provided is a method of treating arterial hypertension in a patient. The method comprises selecting a patient suffering from arterial hypertension and creating a flow pathway between a first vascular location and a second vascular location.
Rox Medical, Inc.


 Magnesium compositions and uses thereof for neurological disorders patent thumbnailnew patent Magnesium compositions and uses thereof for neurological disorders
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound.
Neurocentria, Inc.


 Substituted prolines / piperidines as orexin receptor antagonists patent thumbnailSubstituted prolines / piperidines as orexin receptor antagonists
The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease..
Eolas Therapeutics, Inc.


 Urea compounds and their use as enzyme inhibitors patent thumbnailUrea compounds and their use as enzyme inhibitors
Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis..

 Treatment of the complications of chronic liver disease with caspase inhibitors patent thumbnailTreatment of the complications of chronic liver disease with caspase inhibitors
Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions for reducing the progression of the clinical complications associated with portal hypertension by administering the caspase inhibitors described herein..
Conatus Pharmaceuticals, Inc.


 Salt-free miso production method, salt-free miso, hepatic function improvement agent, and hypertension improvement agent patent thumbnailSalt-free miso production method, salt-free miso, hepatic function improvement agent, and hypertension improvement agent
Provided are: a production method for salt-free miso, in which steamed soy beans and koji are pressurized, heated, and fermented; salt-free miso obtained by said production method; and a hepatic function improvement agent and a hypertension improvement agent that contain said salt-free miso as an effective component thereof.. .
Masuyamiso Co., Ltd.


 Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids patent thumbnailPrevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating diseases, including focal segmental glomerulosclerosis or pulmonary arterial hypertension. The compositions of such embodiments include activated fatty acids such as alkyl substituted fatty acids, keto fatty acids and nitro fatty acids.
Complexa, Inc.


 Method of testing for pulmonary hypertension patent thumbnailMethod of testing for pulmonary hypertension
A primary object of the present invention is to provide a method for conveniently and accurately testing for pulmonary hypertension. To achieve this object, the present invention provides a method for testing for pulmonary hypertension using as an indicator the concentration of selenoprotein p protein in a sample derived from a subject..
Tohoku University


 Pulmonary hypertension biomarker patent thumbnailPulmonary hypertension biomarker
Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension.
Novartis Ag


 Carboxamide inhibitors patent thumbnailCarboxamide inhibitors
The compounds of formula i demonstrate properties as smurf-1 inhibitors and are thus useful in the treatment of a range of disorders, particularly pulmonary arterial hypertension.. .

Carboxamide inhibitors

The compounds of formula i demonstrate properties as smurf-1 inhibitors and are thus useful in the treatment of a range of disorders, particularly pulmonary arterial hypertension.. .

Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria

The present invention relates to a pharmaceutical and food composition for treating, preventing, or alleviating a metabolic disease, containing, as an active ingredient, extracellular vesicles derived from akkermansia muciniphila. The composition of the present invention can be used as a pharmaceutical/food composition and the like for treating, preventing, or alleviating metabolic diseases, in particular metabolic diseases such as obesity, diabetes, hyperlipidemia, arteriosclerosis, and hypertension, occurring or exacerbated due to a high fat diet.
Md Healthcare Inc.

Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof

Provided herein are multiple solid forms of a defined α,{acute over (ω)}-disubstituted dihydroxy cyclopentyl compound, and methods for the preparation and use thereof. In one aspect, there are provided crystalline forms of said cyclopentyl compound, and methods for the preparation and use thereof.
Allergan, Inc.

Treprostinil derivative compounds and methods of using same

Compounds represented by formulae i, ii, iii, and iv including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (ph) or pulmonary arterial hypertension (pah).
Corsair Pharma Inc.

Therapy for complications of diabetes

A method for enhancing glycemic control and/or insulin sensitivity to a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin a (eta) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective eta receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective eta receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension.
Abbvie Deutschland Gmbh & Co. Kg

Methods of treating intraocular pressure with activators of tie-2

Disclosed herein are compounds effective for activation of tie-2 and inhibition of hptp-beta. The compounds can provide effective therapy for eye conditions associated with angiogenesis, for example, intraocular pressure, ocular hypertension, and glaucoma..
Aerpio Therapeutics, Inc.

Mif inhibitors for the acute or chronic treatment of pulmonary hypertension

The present invention relates to the use of compounds of general formula i and pharmaceutically acceptable enantiomers, salts or solvates thereof, for treating pulmonary hypertension in a subject.. .
UniversitÉ Paris-sud 11

Diabetes and hypertension screening by assessment of arterial stiffness and autonomic function

The present invention provides methods and apparatuses to assess vascular stiffness of a subject, and to assess diabetes or hypertension from the assessment of vascular stiffness. Example embodiments comprise determining arrival at a peripheral site of a blood pressure wave as a function of time relative to the cardiac cycle of the subject at a plurality of measurement conditions, wherein at least two of the conditions are characterized by at least one of: (a) different central transmural pressure, (b) different peripheral transmural pressure; assessing vascular stiffness from the determinations at the plurality of measurement conditions..
Medici Technologies, Llc

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.

Use of modified vasoactive intestinal peptides in the treatment of hypertension

The present invention is based on the discovery that a vip having a binding preference for vpac2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful for the treatment and/or amelioration of hypertension are provided..
Phasebio Pharmaceuticals, Inc.

Serca2 therapeutic compositions and methods of use

The present invention provides methods for treating pulmonary hypertension in a subject by delivering a therapeutic adeno-associated virus (aav)-serca2 composition to a subject in need thereof.. .
Icahn School Of Medicine At Mount Sinai

Ablation targeting nerves in or near the inferior vena cava and/or abdominal aorta for treatment of hypertension

A method for the treatment of a patient for the purpose of lowering blood pressure and/or treating other medical conditions such as cardiac arrhythmias. A catheter having an ablation element is placed inside the body of a patient and is directed to a targeted location either on in the abdominal aorta where the right or left renal arteries branch from the aorta at or near the superior junction or ostia or on the inside of the inferior vena cava near the junction with the right renal vein or in the left renal vein at a position spatially near where the left renal artery branches from the abdominal aorta.
Biosense Webster (israel), Ltd.

Methods for therapeutic renal neuromodulation

Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.

Methods and materials for treating elevated sympathetic nerve activity conditions

This document provides methods and materials involved in treating hypertension (e.g., age-associated hypertension, resistant hypertension, or chronic refractory hypertension), heart failure (e.g., congestive heart failure), or kidney disease (e.g., chronic kidney disease). For example, methods and materials involved in administering one or more sympatholytic agents to a patient to identify the patient as having an elevated baseline level of sympathetic nerve activity and treating the identified patient with a sympatholytic therapy to reduce the symptoms of hypertension (e.g., resistant hypertension), heart failure (e.g., congestive heart failure), or kidney disease (e.g., chronic kidney disease) are provided..
Mayo Foundation For Medical Education And Research

Heteroaromatic compounds and their use as dopamine d1 ligands

And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, impulsivity, compulsive gambling, overeating, autism spectrum disorder, mcl, age-related cognitive decline, dementia, rls, parkinson's disease, huntington's chorea, anxiety, depression, mdd, trd, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, sle, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.. .

Substituted pyridazines as prostacyclin receptor modulators

Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.

Method of reducing renal hypertension and computer-readable medium

A method of reducing renal hypertension applied for electrically stimulating a target zone of an organism having a symptom of renal hypertension by using an electronic stimulation device. The electronic stimulation device comprises at least one electronic stimulation unit.
Gimer Medical Co., Ltd.

Prostamide-containing intraocular implants and methods of use thereof

Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle.
Allergan, Inc.

Systems, methods, techniques, and compounds in research and treatment of portal hypertension and other conditions

Methods and compounds for research and treatment of portal hypertension. The use of racemic or non-racemic mixtures of furopyridine isomers to stimulate enos function in sinusoidal endothelial cells and to increase no production in both normal sinusoidal endothelial cells and injured endothelial cells..

Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors

The disclosed subject matter provides certain n-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or development of a disease or condition.
The Johns Hopkins University

Prostacyclin compounds, compositions and methods of use thereof

Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear c5-c18 alkyl, branched c5-c18 alkyl, linear c2-c18 alkenyl, branched c3-c18 alkenyl, aryl, aryl-c1-c18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described.
Insmed Incorporated

Novel formulations and methods

Nanoparticles comprising vip and their use in treating, e.g., pulmonary hypertension. Such nanoparticles provide improved delivery of vip and allow for acute treatment and optionally for sustained release of vip in a patient..
Avant Garde Therapeutics And Technologies, Llc

Intraocular pressure modification

Assemblies and methods for modifying an intraocular pressure of a patient's one or both eyes are disclosed. The assemblies and methods can be used to treat, inhibit, or prevent ocular conditions such as glaucoma, high intraocular pressure, optic disc edema, idiopathic intracranial hypertension, zero-gravity induced papilledema, and other optic pressure related conditions.
Dr. John Berdahl



Hypertension topics:
  • Hypertension
  • Cardiovascular
  • Vascular Disease
  • Cardiovascular Disease
  • Nephropathy
  • Inflammation
  • Aldosterone
  • Dysfunction
  • Blood Pressure
  • Therapeutics
  • Osteoporosis
  • Endothelial
  • Congestive Heart Failure
  • Steoporosis
  • Endothelial Dysfunction


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Hypertension for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Hypertension with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.2333

    file did exist - 2967

    2 - 1 - 56